Moleculin Biotech secures Hong Kong patent for liposomal Annamycin reconstitution method

Moleculin Biotech, Inc.

Moleculin Biotech, Inc.

MBRX

0.00
  • Moleculin Biotech won a Hong Kong patent covering its method of reconstituting liposomal Annamycin, extending protection through June 25, 2040.
  • Patent, No. 40073244, is jointly owned with University of Texas System.
  • Move expands intellectual property coverage for lead cancer drug candidate ahead of expected first Phase 3 data release later this quarter.
  • Annamycin is being developed for relapsed or refractory acute myeloid leukemia, with a separate program in soft tissue sarcoma lung metastases.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moleculin Biotech Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605080845PRIMZONEFULLFEED9716187) on May 08, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.